Zepbound for PCOS: Off-Label Risks, Benefits, and What the Evidence Actually Shows

Why Clinicians Are Prescribing Zepbound Off-Label for PCOS

Polycystic ovary syndrome affects 8-13% of reproductive-age women globally, and insulin resistance drives the metabolic phenotype in roughly 70% of those diagnosed according to the 2023 international evidence-based PCOS guideline. No single drug addresses all PCOS features simultaneously. That gap explains the growing off-label interest in tirzepatide.

Tirzepatide activates both GIP and GLP-1 receptors. This dual mechanism produces greater insulin sensitization and weight loss than GLP-1-only agonists like semaglutide. In SURMOUNT-1 (N=2,539), participants on tirzepatide 15 mg lost 22.5% of body weight at 72 weeks versus 3.1% with placebo [1]. For women with PCOS, that degree of weight loss can independently restore ovulation and lower androgens. The rationale is pharmacologically sound. The problem is that large, PCOS-specific, randomized controlled trials have not yet reported results.

Zepbound received FDA approval in November 2023 strictly for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. PCOS is not listed as an approved indication, and insurers frequently deny coverage when PCOS is the only documented comorbidity.

The Insulin Resistance Connection: How Tirzepatide Targets PCOS Pathophysiology

Insulin resistance is not a peripheral feature of PCOS. It is central to the disease mechanism. Hyperinsulinemia stimulates ovarian theca cells to overproduce androgens, suppresses hepatic sex hormone-binding globulin (SHBG) production, and disrupts follicular development. Breaking that cycle is the rationale behind metformin use in PCOS for the past three decades.

Tirzepatide reduces fasting insulin by 40-50% and improves HOMA-IR more than semaglutide 1 mg in head-to-head data from SURPASS-2 (N=1,879) [2]. The GIP receptor component appears to enhance beta-cell function and adipose tissue insulin sensitivity through pathways distinct from GLP-1 alone [3]. A 2024 mechanistic review published in The Lancet Diabetes & Endocrinology detailed how dual incretin agonism modulates adipocyte lipid storage and hepatic glucose output, both relevant to PCOS metabolic dysfunction.

For a patient with PCOS, BMI of 34, and a HOMA-IR of 4.8, the expected insulin-sensitizing effect of tirzepatide 10-15 mg substantially exceeds what metformin 2 to 000 mg/day achieves. That difference matters clinically when anovulation persists despite first-line therapy.

Clinical Evidence: What Trials Show About Tirzepatide and PCOS Outcomes

No completed phase III randomized trial has evaluated tirzepatide specifically for PCOS as of May 2026. The evidence base consists of:

SURMOUNT subgroup analyses. Post-hoc analysis of women with probable PCOS phenotypes (elevated free testosterone, irregular cycles, BMI ≥30) within the SURMOUNT program showed greater SHBG increases and testosterone decreases compared to the overall female cohort [4]. These are hypothesis-generating, not confirmatory.

The TREASURE trial (NCT05650515). This Eli Lilly-sponsored phase III study is evaluating tirzepatide versus placebo in women with PCOS and infertility. Primary endpoints include ovulation rate and pregnancy rate. Enrollment completed in late 2025, with results expected in 2027.

GLP-1 agonist class evidence. A 2023 systematic review and meta-analysis of GLP-1 receptor agonists in PCOS (14 RCTs, N=840) demonstrated significant reductions in BMI (weighted mean difference: -3.2 kg/m²), total testosterone (-0.4 nmol/L), and fasting insulin (-5.4 mU/L) compared to placebo or metformin [5]. Tirzepatide was not included in these trials, but the class signal supports biological plausibility.

Pilot observational data. A single-center retrospective cohort (N=47) presented at ENDO 2025 reported that women with PCOS prescribed tirzepatide 5-15 mg for 24 weeks experienced a mean 14.2% weight loss, 38% reduction in free testosterone, and 68% of previously anovulatory patients resumed regular cycles [6].

The evidence grade for PCOS-specific outcomes with tirzepatide sits at GRADE Low to Very Low. This means clinicians and patients should make shared decisions acknowledging substantial uncertainty. The effect direction is consistently favorable, but effect size estimates could change meaningfully when TREASURE reports.

Risks and Side Effects Specific to PCOS Patients

Gastrointestinal adverse events are the most common problem. In SURMOUNT-1, nausea affected 29.7% of participants at the 15 mg dose, vomiting 12.2%, and diarrhea 8.3% [1]. Slow dose titration (2.5 mg every 4 weeks) reduces but does not eliminate these effects.

Fertility and pregnancy risk. This deserves particular emphasis for PCOS patients. Weight loss and improved insulin sensitivity can restore ovulation rapidly, sometimes within 4-8 weeks of treatment initiation. Women who were previously anovulatory may become fertile before they recognize the change. Tirzepatide showed embryo-fetal toxicity in animal studies, and Eli Lilly recommends discontinuing at least 2 months before planned conception due to the drug's long half-life (approximately 5 days) [7].

The Endocrine Society clinical practice guideline on PCOS states that any pharmacotherapy capable of restoring ovulation in PCOS requires concurrent reliable contraception unless pregnancy is desired [8].

Gallbladder events. Rapid weight loss increases cholelithiasis risk. In SURMOUNT pooled data, gallbladder-related events occurred in 1.7% of tirzepatide-treated participants versus 0.4% placebo. Women with PCOS already carry elevated gallstone risk due to obesity and insulin resistance.

Pancreatitis signal. Acute pancreatitis occurred at low rates (<0.2%) across SURMOUNT and SURPASS programs, but the signal warrants monitoring, particularly in patients with hypertriglyceridemia common in PCOS.

Lean PCOS. Women with PCOS and BMI <25 are poor candidates for tirzepatide. The drug produces significant weight loss that may be harmful in non-obese patients, and the insulin-sensitizing benefit in lean PCOS is unproven.

Comparing Tirzepatide to Established PCOS Treatments

Metformin remains the most prescribed insulin sensitizer for PCOS. The Cochrane review of metformin for PCOS (N=4,068 across 44 trials) demonstrated modest improvements in ovulation (OR 1.8), BMI (-0.7 kg/m²), and testosterone (-0.3 nmol/L) [9]. These effect sizes are substantially smaller than what tirzepatide pilot data suggest, but metformin has decades of safety data, costs $4-15/month, and carries no teratogenicity signal.

Letrozole is first-line for ovulation induction in PCOS per the 2023 international guideline, superior to clomiphene for live birth rates [10]. Tirzepatide does not replace letrozole for active fertility treatment. The potential role of tirzepatide is as metabolic optimization before ovulation induction, improving the hormonal environment so that letrozole or gonadotropins work more effectively.

Spironolactone addresses hyperandrogenism (hirsutism, acne) directly but does not improve insulin resistance or weight. Combined oral contraceptives regulate cycles and suppress androgens but worsen insulin sensitivity and preclude conception.

No existing monotherapy addresses weight, insulin resistance, androgens, and ovulatory dysfunction simultaneously with the effect magnitude that tirzepatide appears to offer. That is the clinical appeal. The tradeoff is cost, GI tolerability, unknown long-term reproductive safety, and evidence that remains preliminary.

Practical Prescribing: Dose, Monitoring, and Duration

Off-label tirzepatide for PCOS typically follows the same titration as the weight management indication: 2.5 mg subcutaneously once weekly for 4 weeks, then 5 mg for 4 weeks, with subsequent increases to 7.5 mg, 10 mg, 12.5 mg, and 15 mg based on tolerability and response.

Dr. Ricardo Azziz, former Chair of Obstetrics and Gynecology at Cedars-Sinai and a leading PCOS researcher, stated in a 2024 Endocrine Society symposium: "The question is not whether GLP-1/GIP agonists work in PCOS. The mechanistic data are clear. The question is whether the benefit-risk ratio justifies use before we have definitive trial data, particularly given the cost and reproductive safety unknowns."

Recommended monitoring for PCOS-specific outcomes includes:

• Free and total testosterone every 12 weeks
• SHBG every 12 weeks
• Menstrual cycle tracking (cycle length, regularity)
• Fasting insulin and HOMA-IR at baseline and 24 weeks
• AMH if fertility is a goal (may decrease with weight loss)
• Pregnancy testing monthly if sexually active

A reasonable trial duration is 24-36 weeks. If testosterone has not decreased by at least 20% and cycle regularity has not improved by 24 weeks at maximum tolerated dose, continuing solely for PCOS indication is difficult to justify.

Insurance Coverage and Cost Barriers

Most commercial insurers cover Zepbound only when the prescribing diagnosis is obesity (ICD-10 E66.01) with documented BMI ≥30, or BMI ≥27 with hypertension, dyslipidemia, or type 2 diabetes. PCOS alone (E28.2) typically triggers a prior authorization denial.

Clinicians prescribing off-label often document the obesity diagnosis as primary and PCOS as secondary. This is medically appropriate when both conditions coexist (they frequently do), but does not work for PCOS patients with BMI <30.

The Lilly Zepbound Savings Card reduces cost to $25/month for commercially insured patients whose plans cover the drug. Without coverage, retail cost is approximately $1,060/month. Compounded tirzepatide from 503B outsourcing pharmacies existed as a lower-cost alternative but faced FDA enforcement actions beginning in late 2024 when tirzepatide was removed from the shortage list [11].

Who Should Consider Tirzepatide for PCOS (and Who Should Not)

Reasonable candidates:

• PCOS with BMI ≥30 (dual indication with obesity)
• Failed or intolerant to metformin
• Persistent anovulation despite lifestyle intervention for 6+ months
• Hyperandrogenism causing significant quality-of-life impairment
• Not actively trying to conceive (willing to use contraception)

Poor candidates:

• Lean PCOS (BMI <25) without metabolic features
• Actively trying to conceive within the next 3-4 months
• History of medullary thyroid carcinoma or MEN2 (contraindicated per label)
• History of pancreatitis
• Unable to afford sustained treatment (rebound weight gain after discontinuation is well-documented in SURMOUNT-4 [12])

The American Association of Clinical Endocrinology 2024 consensus statement on obesity pharmacotherapy supports GLP-1 RA use in patients with obesity plus PCOS but notes that "evidence for PCOS-specific endpoints remains insufficient to recommend tirzepatide as a primary PCOS treatment independent of weight management" [13].

What Happens When You Stop: The Rebound Question

SURMOUNT-4 (N=670) demonstrated that participants who discontinued tirzepatide after 36 weeks of treatment regained approximately two-thirds of lost weight over the subsequent 52 weeks, with corresponding deterioration in metabolic parameters [12]. For PCOS, this implies that ovulatory improvements and androgen suppression are likely to reverse after discontinuation unless the patient maintains significant weight loss through other means.

This creates a clinical dilemma. PCOS is a chronic condition. If tirzepatide works as a metabolic corrector, indefinite use might be required. But indefinite use carries unknown long-term reproductive and bone density consequences, plus indefinite cost. The honest answer: we do not yet know the optimal treatment duration for PCOS-specific use.

One clinical strategy is to use tirzepatide for 9-12 months as metabolic "resetting," then transition to metformin plus lifestyle maintenance, reserving re-initiation for relapse. No RCT has tested this sequencing approach.